Biliary tumors, primarily cholangiocarcinomas, arise from the bile ducts and can be classified as intrahepatic or extrahepatic based on their location. These tumors are often aggressive and can cause symptoms like jaundice due to bile obstruction. Risk factors include chronic liver diseases and infections. The diagnosis typically involves imaging and biopsy, while treatment options may include surgery, chemotherapy, and palliative care. Early detection is crucial, as prognosis is generally poor with advanced disease stages.
Major companies involved in the biliary tumors treatment market include Eli Lilly and Company, Merck Sharp & Dohme LLC and AstraZeneca, among others.
Leading drugs currently under the pipeline include ramucirumab and pembrolizumab, among others.
The increasing cases of biliary tumors and the rising technological advancements are poised to positively influence the biliary tumors pipeline landscape.
The Biliary Tumors Pipeline Analysis Report by Expert Market Research gives comprehensive insights into biliary tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for biliary tumors. The biliary tumors report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The biliary tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with biliary tumors treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to biliary tumors.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Biliary cancer (mainly cholangiocarcinomas) is caused by chronic inflammation and genetic changes in bile duct cells (cholangiocytes). Biliary intraepithelial neoplasia (BilIN) develops when persistent inflammation from diseases such as primary sclerosing cholangitis, liver cirrhosis, or biliary cysts causes metaplasia and dysplasia. KRAS mutations account for 40% of the cases and are considered early molecular events. Later, TP53 mutations lead to malignant transformation. These tumors cause liver malfunction and jaundice by blocking bile ducts. Modern molecular classifications have improved diagnosis accuracy by identifying subtypes with unique therapy targets. Due to delayed discovery, the prognosis is still dismal; for intrahepatic variations, the 5-year survival rate is less than 20%.
The location and stage of the malignancy determine how biliary tumors are treated. The sole remaining treatment is surgery, which may include partial liver resection and tumor removal. Palliative treatments including stenting, percutaneous drainage, or photodynamic therapy reduce symptoms like jaundice in instances that are advanced or incurable. Chemotherapy (such as gemcitabine and cisplatin), immunotherapy, and targeted medicines for genetic alterations (such as FGFR2, IDH1) are examples of systemic treatments. Although promising, emerging approaches like as CAR-T cell therapy encounter obstacles because of the tumor's immunosuppressive microenvironment.
Biliary tumors, such as gallbladder cancer and cholangiocarcinoma, vary by region. About 8,000 persons in the United States are affected with bile duct cancer each year. Intrahepatic cases are more prevalent than extrahepatic ones. Intrahepatic and extrahepatic malignancies have respective incidence rates of 1.49 and 0.96 per 100,000 people. Because of risk factors such as liver flukes, Southeast Asia and South America report greater prevalences worldwide. Globally, intrahepatic cholangiocarcinoma has become more common, especially in men.
This section of the report covers the analysis of biliary tumors drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of biliary tumors drugs undergoing clinical development.
The drug molecule categories covered under biliary tumors pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The biliary tumors report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for biliary tumors.
The EMR report for the biliary tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed biliary tumors therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in biliary tumors clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for biliary tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of biliary tumors drug candidates:
Ramucirumab by Eli Lilly and Company is being evaluated in a Phase 2 clinical trial for patients with advanced biliary tumors. The study assesses the efficacy and safety of Ramucirumab, an anti-VEGFR2 monoclonal antibody, in combination with paclitaxel. The goal is to determine its potential to improve progression-free survival and overall clinical outcomes. This industry-funded trial targets individuals with biliary tract cancers who have progressed on previous therapies.
Pembrolizumab by Merck Sharp & Dohme LLC is being studied in a Phase 3 clinical trial for patients with advanced biliary tumors. The trial evaluates the safety and efficacy of pembrolizumab, an anti-PD-1 monoclonal antibody, as part of an immunotherapy regimen. The study aims to determine its potential in prolonging survival and improving clinical outcomes in individuals with biliary tract cancers who have progressed after prior treatments.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Biliary Tumors Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for biliary tumors. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into biliary tumor collaborations, regulatory environments, and potential growth opportunities.
Upto 35% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share